Comerica Bank Reduces Holdings in Haemonetics Co. (NYSE:HAE)

Comerica Bank reduced its stake in Haemonetics Co. (NYSE:HAE - Free Report) by 10.7% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 67,512 shares of the medical instruments supplier's stock after selling 8,091 shares during the quarter. Comerica Bank owned 0.13% of Haemonetics worth $5,271,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in HAE. TD Waterhouse Canada Inc. acquired a new position in shares of Haemonetics in the 4th quarter worth approximately $25,000. Covestor Ltd lifted its holdings in shares of Haemonetics by 146.8% in the 4th quarter. Covestor Ltd now owns 738 shares of the medical instruments supplier's stock worth $58,000 after acquiring an additional 439 shares during the last quarter. Whittier Trust Co. acquired a new position in shares of Haemonetics in the 4th quarter worth approximately $62,000. Parkside Financial Bank & Trust lifted its holdings in shares of Haemonetics by 25.6% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier's stock worth $92,000 after acquiring an additional 240 shares during the last quarter. Finally, AlphaQuest LLC lifted its holdings in shares of Haemonetics by 36,520.0% in the 4th quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier's stock worth $143,000 after acquiring an additional 1,826 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Haemonetics Stock Up 0.3%

Shares of NYSE:HAE traded up $0.20 during trading hours on Friday, reaching $68.21. The stock had a trading volume of 782,442 shares, compared to its average volume of 694,988. Haemonetics Co. has a 1 year low of $55.30 and a 1 year high of $97.97. The firm's 50 day moving average is $62.75 and its 200-day moving average is $71.36. The company has a debt-to-equity ratio of 1.35, a quick ratio of 2.55 and a current ratio of 3.97. The stock has a market capitalization of $3.43 billion, a price-to-earnings ratio of 26.85, a P/E/G ratio of 1.11 and a beta of 0.32.

Haemonetics (NYSE:HAE - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.24 EPS for the quarter, beating analysts' consensus estimates of $1.22 by $0.02. Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. The company had revenue of $330.60 million for the quarter, compared to the consensus estimate of $329.38 million. During the same period in the prior year, the firm posted $0.90 EPS. The company's quarterly revenue was down 3.5% compared to the same quarter last year. Research analysts predict that Haemonetics Co. will post 4.55 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. StockNews.com upgraded shares of Haemonetics from a "hold" rating to a "buy" rating in a report on Monday, May 5th. Needham & Company LLC reduced their target price on shares of Haemonetics from $104.00 to $84.00 and set a "buy" rating on the stock in a report on Thursday. JMP Securities reduced their target price on shares of Haemonetics from $125.00 to $100.00 and set a "market outperform" rating on the stock in a report on Friday, February 7th. Barrington Research reduced their target price on shares of Haemonetics from $108.00 to $95.00 and set an "outperform" rating on the stock in a report on Friday, February 7th. Finally, Raymond James reiterated a "strong-buy" rating and set a $105.00 target price (down from $115.00) on shares of Haemonetics in a report on Friday. One research analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $97.89.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.